Buyback Plan Overview - The company approved a share buyback plan on February 27, 2025, with a total amount between 90 million yuan and 160 million yuan, and a maximum buyback price of 31.65 yuan per share, estimating to repurchase approximately 2.84 million to 5.06 million shares, representing about 0.5354% to 0.9519% of the total share capital as of the announcement date [1] - The buyback period is set to last no more than twelve months from the board's approval date [1] - Due to the company's 2024 annual equity distribution, the maximum buyback price was adjusted to 31.27 yuan per share starting July 10, 2025, and further adjusted to 31.05 yuan per share from September 22, 2025 [1] Latest Buyback Progress - As of September 30, 2025, the company repurchased 2,673,910 shares, accounting for 0.47% of the total share capital, with a total transaction amount of approximately 58.92 million yuan, and the buyback prices ranged from 20.31 yuan to 23.00 yuan per share [2] - On June 4, 2025, the company transferred 581,460 shares to the 2024 employee stock ownership plan, leaving 2,092,450 shares in the buyback account as of September 30, 2025 [2] Compliance Statement - The company's share buyback activities comply with relevant regulations regarding timing, quantity, price, and trading methods, ensuring no repurchases occurred during periods of significant price impact or other restricted conditions [3] Future Plans - The company plans to continue the buyback program in accordance with market conditions and will disclose information in a timely manner as required by regulations [4]
奇正藏药回购进展:已回购267.39万股,金额达5892.35万元